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plasm and the nucleus was more common (p = 0.9).  Conclu-
sions: The lower Gal-3 expression in MF-T in comparison to 
CD30 LPD might be an additional criterion to differentiate 
both entities. The different sublocalization of the Gal-3 signal 
might reflect a different biological function and behavior. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Primary cutaneous CD30+ lymphoproliferative disor-
ders (CD30 LPD) are the second most common form of 
cutaneous T-cell lymphoma  [1, 2] . By definition, cutane-
ous lymphoma is limited to the skin at the time of diag-
nosis. The group of CD30 LPD includes primary cutane-
ous anaplastic large cell lymphoma (PCALCL) and lym-
phomatoid papulosis (LYP)  [1] . PCALCL presents 
clinically most commonly with a solitary and often ulcer-
ated nodule or localized tumors. Histopathologically the 
infiltrate consists of large pleomorphic, anaplastic or im-
munoblast-like tumor cells expressing CD30 (by defini-
tion >75%)  [1] . LYP is a chronic recurrent eruption, char-
acterized by a typical waxing and waning course with self-
healing papules and nodules. The 3 main histological 
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 Abstract 
 Background: In nodal anaplastic large cell lymphoma, 
strong expression of galectin-3 (Gal-3) has been found, but 
only very few cases of primary cutaneous lymphoma have so 
far been examined.  Objectives: To investigate 11 primary
cutaneous anaplastic large cell lymphomas (PCALCL), 47 
lymphomatoid papuloses (LYP) and 14 cases of transformed 
mycosis fungoides with CD30 expression (MF-T) for Gal-3 ex-
pression.  Methods:  A Gal-3 score was applied using a 
photo-based morphometric evaluation program. Double 
staining for CD30 and Gal-3 was performed. Furthermore, we 
recorded the cellular and extracellular sublocalization of the 
signal.  Results: The Gal-3 expression in CD30+ tumor cells 
was significantly lower in MF-T in contrast to CD30+ lympho-
proliferative disorders (CD30 LPD; p < 0.001), but we found 
no differences between PCALCL and LYP (p = 0.42). In
PCALCL Gal-3 was more often localized in the cytoplasm in 
contrast to LYP, in which an equal distribution in the cyto-
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types are: LYP type A (so-called histiocytic type), type B 
(mycosis fungoides-like type), type C (anaplastic large 
cell lymphoma (ALCL)-like type). Moreover, 3 estab-
lished further types have been described  [1] .
 However, CD30 expression is not restricted to this 
group and is also found in immunosuppression-related 
CD30 LPD, in systemic ALCL, Hodgkin’s lymphoma and 
some cases of mycosis fungoides (MF)  [1] . Because of the 
broad spectrum of lymphoproliferations with expression 
of CD30, clinicopathological correlation and staging pro-
cedures are indispensable in the diagnostic workup.
 Galectins are a family (β-galactoside-binding lectin 
family) of proteins defined by their binding specificity for 
β-galactoside sugars  [3] . In mammals 15 galectins have 
been discovered, but only galectin types 1, 2, 3, 4, 7, 8, 9, 
10, 12 and 13 have been identified in humans. One of the 
best studied is galectin-3 (Gal-3), which plays a physio-
logical role in the regulation of cell proliferation and 
apoptosis, and in malignant tumor cell proliferation  [4, 
5] . Gal-3 is physiologically expressed in macrophages and 
dendritic cells in tonsils but, in contrast, normal lympho-
cytes are predominantly negative  [6] . Gal-3 has been 
studied in several solid tumors  [7, 8] , but only limited 
data are available on its expression in lymphoma  [6, 9, 
10] .
 It has been reported that Gal-3 is consistently ex-
pressed in ALCL, but only 2 cases of PCALCL have been 
investigated so far  [6, 10] . In these 2 cases, the neoplastic 
cells expressed Gal-3, whereas the 1 case of LYP examined 
so far was negative for Gal-3  [10] . These sparse data sug-
gest differences in the expression of Gal-3 in CD30 LPD. 
Therefore, our aim was to investigate Gal-3 expression in 
primary cutaneous CD30 LPD and CD30-expressing 
transformed MF (MF-T).
 Material and Methods 
 Patients and Samples 
 Fifty-eight skin biopsies of CD30+ LPD were diagnosed and 
reviewed by 3 board-certified dermatopathologists (W.K., A.R., 
C.M.). The biopsies included specimens of 11 PCALCL biopsies 
from 11 patients, and 47 LYP biopsies from 40 patients. We also 
investigated 14 biopsies of MF-T with CD30 expression from a to-
tal of 12 patients. Clinical information was obtained by retrospec-
tive note review and communication with clinicians and patients. 
The data of the patients were stored in a database.
 Histology and Immunohistochemistry 
 Biopsy specimens were fixed in 10% buffered formalin and em-
bedded in paraffin, hematoxylin and eosin stained and reviewed. 
Immunohistochemical studies were conducted using the follow-
ing antibodies: CD30 (Novocastra/Leica-Microsystems, Newcas-
tle, UK, clone JMC 182, dilution 1: 50), Gal-3 (Cell Marque, Rock-
lin, Calif., USA, clone 9C4, dilution 1: 80). Double stainings were 
performed for CD30 and Gal-3. Sections from human tonsils (for 
Gal-3) and from nodal ALCL (for CD30) were used as positive 
controls.
 Evaluation of the Slides 
 Gal-3 Expression in Relation to the Entire Lymphocytic 
Infiltrate 
 The Gal-3 expression was evaluated in relation to the entire 
lymphocytic infiltrate. To determine the share of Gal-3+ cells in 
relation to the entire infiltrate, a score was created. Among the 
CD30+ tumor cells, the reactive infiltrate, such as T lymphocytes 
and histiocytes, could be Gal-3+. This ‘Gal-3 score’ was based on 
the well-established ‘h-score’, which was introduced to quantify 
immunohistochemical staining for hormone receptor expression 
in tumors  [11] . For evaluation a photo-based morphometric eval-
uation program (NIS elements software, Nikon Ni-U microscope) 
was used.
 A mean of 352 cells were investigated per case. For analysis, 
from each selected representative area a screen shot was made. All 
lymphocytes were tagged by the investigator according to their 
staining intensity (strong = A, weak = B and negative = C;  fig. 1 ). 
After that, the cells were counted automatically by the program 
with respect to the described subgroups. The Gal-3 score was de-
termined by multiplication (number of cells with strong expres-
sion by 2, with weak expression by 1). After that these results were 
added and divided by the number of all investigated cells and mul-
tiplied by 100 to avoid decimal numbers:
 Gal-3 score = [(A × 2 + B × 1)/(A + B + C)] × 100.
 Fig. 1. Exemplary picture for the evaluation of the Gal-3 score. All 
lymphocytes were tagged by the investigator according to their 
staining intensity (strong = A, weak = B and negative = C). These 
cells were automatically counted by a photo-based morphometric 
evaluation program with respect to the described subgroups. 
×400. 
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 Gal-3 Expression in Relation to CD30+ Tumor Cells 
 To investigate the Gal-3 expression only in the CD30+ tumor 
cells, double staining was performed in 60 cases. 200 CD30+ tumor 
cells in a representative area were examined for Gal-3 coexpres-
sion; the results were given as a percentage.
 Subcellular Localization of Gal-3 Expression 
 We recorded the subcellular localization of Gal-3 staining. This 
was classified into 3 groups as follows: 1 = predominantly nuclear 
expression; 2 = predominantly cytoplasmic expression, and 3 = equal 
distribution of nuclear and cytoplasmic expression. Furthermore, we 
recorded the extracellular localization of the signal, if present.
 Statistical Analysis 
 All statistical analyses were carried out using SPSS 22. To ac-
count for nonnormal data distribution, Mann-Whitney U tests 
were used to compare PCALCL versus LYP, PCALCL versus
MF-T, CD30 LPD versus MF-T, PCALCL and LYP type C versus 
MF-T, as well as LYP type A versus LYP type C regarding the Gal-
3 score. Differences between LYP and PCALCL and between LYP 
type A and LYP type C regarding the relationship between Gal-3 
and the whole infiltrate were investigated by t tests. For analysis of 
the cellular sublocalization of the Gal-3 staining, Fisher’s exact test 
was used. A significance level p < 0.05 was applied for all tests. No 
statistical subgroup analyses were performed for LYP type B, be-
cause only 1 case was included in our study.
 Results 
 Patient Characteristics 
 We investigated 58 biopsy specimens of 51 patients. 
The group of CD30 LPD included 11 PCALCL and 47 
LYP biopsies of 11 and 40 patients, respectively. The 
mean age of the patients in PCALCL (LYP) was 58.4 
(51.6) years; 6 (21) were men and 5 (19) were women. 
Moreover, 14 biopsy specimens of 12 patients with MF-T 
were investigated. The mean age of the patients was 58.6 
years; 6 were men and 4 women; in 2 cases, the gender was 
not known. Extracutaneous disease was excluded by stag-
ing according to international guidelines  [1, 12] .
 Histological and Molecular Pathological Findings 
 The diagnosis of PCALCL, LYP and MF-T was based 
on clinicopathological correlation. All cases showed the 
characteristic histological features, as previously de-
scribed  [2] .
 EMA (epithelial membrane antigen) was negative in 
47 of the 54 investigated cases. In 7 cases focal and weak 
EMA expression by tumor cells was found. In all of these 
cases ALK (anaplastic lymphoma kinase) was negative. 
LYP cases were histologically subclassified as type A 
(36), type B (1) and type C (8) as described  [1, 2, 13, 14] . 
In 2 cases a mixed type of A and C was found. No other 
histological LYP types were included. The number of 
CD30+ cells in MF-T showed a mean of 25.4, with a 
wide range between 5 and 70. Therefore we evaluated 
only the Gal-3 expression in CD30+ cells by double 
staining.
 Immunohistochemical Analysis 
 Expression in Normal Tissue 
 As previously reported  [6, 10] , we found an expression 
of Gal-3 in macrophages and dendritic cells in tonsils 
used as external on-slide positive control.
 Gal-3 Expression in Relation to the Entire 
Lymphocytic Infiltrate 
 Concerning the Gal-3 expression in relation to the
entire infiltrate (Gal-3 score), we found no significant
differences between LYP (mean: 89.67 ± 32.16) and 
PCALCL (mean: 94.09 ± 41.74; p = 0.71;  table 1 ) or LYP 
type C (mean: 108.6 ± 15.6) and PCALCL (t = 1.06, p = 
0.309). However, in relation to the whole infiltrate there 
was a lower Gal-3 score in LYP type A (mean: 87.47 ± 
35.37) than in LYP type C (mean: 108.6 ± 15.6; t = –2.54, 
p = 0.017). We found a homogenous distribution of Gal-
3 throughout the infiltrate. No different staining patterns 
could be distinguished.
 Table 1.  Overview of the results of Gal-3 expression in LYP, PCALCL and MF-T
Cases, n
(n = 66)
Gal-3 coexpression with CD30 Gal-3 score in relation to
the whole infiltrate
Subcellular localization
(predominating pattern)
LYP 47 47.52 (vs. PCALCL p = 0.416) 89.67 (vs. PCALCL p = 0.71) cytoplasmic = nuclear
PCALCL 11 56.40 94.09 cytoplasmic (vs. predominating 
pattern in LYP p = 0.09) 
MF-T 14 5.3 (vs. LYP/PCALCL p < 0.001) n.i. n.i.
Data are expressed as mean values. n.i. = Not investigated.
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 Gal-3 Expression in Relation to the CD30+ Tumor 
Cells 
 Considering only the Gal-3 expression in CD30+ tu-
mor cells, we observed in all cases of CD30 LPD Gal-3 
expression, but in variable proportions. We found no dif-
ferences between LYP (mean 47.52 ± 26.51;  fig. 2 a) and 
PCALCL (mean 56.40 ± 32.95;  fig. 2 b) in CD30/Gal-3 
coexpression (p = 0.416, U = 166.5;  table 1 ). In contrast, 
the expression of Gal-3 in CD30+ tumor cells of MF-T 
was significantly lower (mean 5.3 ± 9.5;  fig. 2 c) in com-
parison to CD30 LPD (including all LYP subtypes; p < 
0.001;  table 1 ) and in particular to PCALCL/LYP type C 
(p < 0.001). The second group reflects the differential di-
agnostically more relevant situation and was therefore 
investigated separately. There were no differences be-
tween Gal-3 expression in LYP type A (48.87 ± 27.6%) 
when compared to LYP type C (50 ± 26.4%; U = 103, p = 
0.836).
 Subcellular Localization of Gal-3 
 All investigated cases showed expression of Gal-3 in 
the nucleus and cytoplasm, but to a variable degree. As a 
trend, in PCALCL Gal-3 was more often localized in the 
cytoplasm ( fig.  3 ; cytoplasmic: 7 cases vs. cytoplasmic/
cba
 Fig. 2. CD30 (red; colors in the online version only)/Gal-3 (brown) double staining. Many CD30/Gal-3 double-expressing cells were 
found in LYP ( a ) and in PCALCL ( b ). Most of the CD30+ cells in MF-T ( c ) were negative for Gal-3 (arrows). ×400. 
 Fig. 3. PCALCL with a predominating cytoplasmic Gal-3 staining. 
×400. 
 Fig. 4. LYP with a more equal distribution of nuclear and cytoplas-
mic staining. ×400. 
Co
lo
r v
er
si
on
 a
va
ila
bl
e 
on
lin
e
Co
lo
r v
er
si
on
 a
va
ila
bl
e 
on
lin
e
Co
lo
r v
er
si
on
 a
va
ila
bl
e 
on
lin
e
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
5/
27
/2
01
6 
11
:1
9:
15
 A
M
 Mitteldorf/Robson/Tronnier/Pfaltz/
Kempf
 
 Dermatology 2015;231:164–170 
DOI: 10.1159/000431313
168
nuclear: 4 cases) in contrast to LYP ( fig. 4 ; cytoplasmic: 
14 cases vs. cytoplasmic/nuclear: 28 cases) in which a 
mostly equal distribution of Gal-3 in the nucleus and the 
cytoplasm was found (p = 0.09;  table 1 ). Predominantly 
nuclear staining was not found in any PCALCL or LYP. 
In 7 cases (2 PCALCL; 5 LYP) an extracellular signal 
( fig. 5 ) could be detected.
 Discussion 
 Gal-3 was reported to be consistently expressed in 
nodal ALCL and to be a useful marker to differentiate 
this entity from Hodgkin’s lymphoma  [6, 10] . To the 
best of our knowledge, only 2 cases of PCALCL and 1 
case of LYP have been investigated so far  [6, 10] . We 
found Gal-3 expression in all investigated CD30 LPD, 
but in contrast to the previous reports the expression in 
PCALCL was not uniform, and the LYP cases in our se-
ries were not negative for Gal-3. In PCALCL only 56.4% 
and in LYP 47.5% (mean values) of the CD30+ cells ex-
pressed Gal-3 with no significant differences between 
the groups. Similar results were obtained concerning the 
whole lymphocytic infiltrate in relation to Gal-3 expres-
sion. In contrast to the reported cases in the literature, 
we used a photo-based morphometric evaluation system 
and performed double staining, which allowed a more 
precise evaluation of Gal-3 expression. This might ac-
count for the different results. Furthermore, very few 
cases have been previously investigated, and these stud-
ies did not include a systematic comparison between 
PCALCL and LYP.
 Gal-3 is a multifunctional protein and regulates a va-
riety of biological processes. For example, it has been re-
ported that Gal-3 can activate neutrophils, e.g. in pneu-
mococcal lung infection  [13] . Therefore it is plausible that 
there might be a relationship between Gal-3 expression 
and the number of neutrophils in the infiltrate. This 
might account for the difference between LYP type A, 
with more admixed neutrophils, and LYP type C, whilst 
finding no difference in Gal-3/CD30 coexpression be-
tween these groups. In relation to the whole infiltrate, we 
found a significantly lower Gal-3 score in LYP type A 
than in LYP type C. This result might reflect only the low-
er number of tumor cells in LYP type A, because no dif-
ference concerning only the CD30+ tumor cells could be 
observed between these types.
 Gal-3 expression in CD30+ tumor cells was signifi-
cantly lower in MF-T when compared to CD30 LPD. De-
spite the relatively small number of MF-T cases, the dif-
ferences in Gal-3 expression between CD30 LPD and 
MF-T indicate that assessment of Gal-3 expression could 
be an additional tool to differentiate between the entities. 
Further investigations are needed to confirm these re-
sults.
 Gal-3 is important for cell growth, cell adhesion and 
cell-cell interaction. Because of its unique structure, Gal-
3 is able to interact with a broad spectrum of ligands. One 
of its natural ligands is the EMA  [14] . EMA is preferen-
tially expressed in ALK-1+ nodal ALCL; PCALCL are 
EMA– in most cases  [15, 16] , as found in the test cases of 
this study. It has been postulated in the literature that 
EMA expression might be induced by the activated ALK-
1 protein  [13, 14] . Moreover, a stable transduction of nu-
cleophosmin-ALK into the cutaneous ALCL cell line 
Mac-1 induces expression of EMA  [17] . The binding be-
tween EMA and Gal-3 might be critical for the different 
biological behavior of ALK-1+ ALCL and PCALCL. It has 
been reported that the subcellular localization of Gal-3 
can be highly variable, not only depending on the cell 
type, but also reflecting the presence or absence of a bind-
ing partner. This study found focal EMA expression in 7 
of 54 investigated cases, but no relation between EMA 
expression and the cellular sublocalization of Gal-3 was 
identified.
 In addition to nuclear, cytoplasmic and cell surface 
localization, galectins can be secreted into the extracel-
lular matrix  [18] . Similar to previous reports on ALK-1+ 
ACLC  [10] , we found Gal-3 staining in the nucleus and 
cytoplasm of neoplastic cells in most cases. The addi-
 Fig. 5. Extracellular detection of Gal-3 in a LYP. ×400. 
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tional extracellular signal of Gal-3 found in a few cases 
might represent secreted Gal-3. Disparate functions, de-
pending on the sublocalization of Gal-3, have been de-
scribed  [19] . Intracytoplasmic Gal-3 expression can in-
hibit the Fas-induced apoptotic pathway  [20, 21] , pro-
mote cell growth and regulate T-cell receptor signal 
transduction  [22] . In contrast, when Gal-3 is secreted 
into the extracellular matrix, it can induce apoptosis by 
interacting with terminal galactose residues on cell sur-
face glycans  [20] . The predominantly cellular localiza-
tion of Gal-3 found in our study may contribute to the 
inhibition of apoptosis and is a possible mechanism of 
immune escape. Interestingly, we found predominantly 
cytoplasmic staining in PCALCL in contrast to LYP, 
which largely had an equal distribution of Gal-3 in the 
nucleus and the cytoplasm. For many solid tumors, a 
shift of Gal-3 from the nucleus to the cytoplasm during 
neoplastic progression has been described  [23, 24] . 
Moreover, in squamous cell carcinoma of the tongue 
this shift of localization seems to have prognostic impor-
tance  [24] . The different subcellular distribution of Gal-
3 in PCALCL and LYP might be a contributing factor to 
the different biological behavior of these entities. In 7 
cases of CD30 LPD, an extracellular Gal-3 signal was 
detectable, 5 of which were LYP cases and only 2
PCALCL. These small numbers preclude meaningful 
statistical analysis and conclusions, but it is possible that 
this might also contribute to the different biological be-
haviors of the groups.
 In summary, Gal-3 is expressed in PCALCL and LYP, 
but to a variable degree. Gal-3 expression in CD30+ tu-
mor cells was significantly lower in MF-T than in CD30 
LPD and might therefore be an additional tool to distin-
guish between these entities histologically. The Gal-3 
scores were different in LYP type A in comparison to LYP 
type C concerning the whole infiltrate, but no differences 
could be observed concerning only Gal-3 expression in 
CD30+ tumor cells. This difference might therefore re-
flect only the lower number of tumor cells in LYP type A. 
We found no significant differences in Gal-3 expression 
between PCALCL and LYP; neither in relation to the en-
tire infiltrate nor to the CD30+ tumor cells. Moreover, we 
found different cellular localizations of Gal-3, which 
might reflect specific biological functions that influence 
tumor cell behavior.
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